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Major depression is the commonest psychiatric disorder and in the U.S. has the greatest impact of all
biomedical diseases on disability. Here we review evidence of the genetic contribution to disease suscepti-
bility and the current state of molecular approaches. Genome-wide association and linkage results provide
constraints on the allele frequencies and effect sizes of susceptibility loci, which we use to interpret the vol-
uminous candidate gene literature. We consider evidence for the genetic heterogeneity of the disorder and
the likelihood that subtypes exist that represent more genetically homogenous conditions than have hitherto
been analyzed.
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A lot is being asked of the genetic analysis of major depression
(MD): to find the biological underpinnings of one of the common-
est psychiatric illnesses and one of the world’s leading causes of
morbidity. While lifetime prevalence estimates vary, from 3% in
Japan to 16.9% in the U.S., in all countries the disorder is com-
mon, with a frequency typically varying from 8% to 12% (Demyt-
tenaere et al., 2004; Kessler et al., 2003). In the U.S., MD has the
greatest impactof all biomedical diseasesondisability; inEurope,
it is the third leading cause of disability (Alonso et al., 2004b; Nier-
enberg et al., 2001; Penninx et al., 2001; Ustu¨n et al., 2004).
Despite its prevalence and MD’s enormous burden on our
health care systems (Scott et al., 2003), our treatments are
almost entirely symptomatic. There is even dispute about the
value of medication (Khin et al., 2011; Kirsch et al., 2008; Turner
et al., 2008; Vo¨hringer and Ghaemi, 2011) and psychological
therapies (Cuijpers et al., 2008, 2010, 2011). Genetic analysis,
by identifying risk variants and thereby increasing our under-
standing of how MD arises, could lead to improved prevention
and the development of new and more effective therapies.
Although genetic analysis has identified risk loci formany other
common medical diseases (Hindorff et al., 2009), success has
yet to visit MD. In this Review, we consider what has so far
been learnt, consider reasons for the difficulties encountered,
and propose how these might be overcome. We start by review-
ing evidence from the genetic epidemiology literature relevant to
the genetic basis of MD. We then consider what genome-wide
association studies (GWASs) have told us. The GWAS results
are particularly important for interpreting the large, forbidding
literature on candidate gene studies, which we review next. In
addition, GWAS findings inform us about the extent to which
rare but more highly penetrant genetic variants might contribute
to liability to MD. We finally examine whether there exist forms of
MD that might be more genetically homogeneous and consider
how these might be identified.
Genetic Epidemiology
Studies showing thatMD aggregates within families date back to
the early decades of the 20th century (reviewed in Tsuang and484 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.Faraone, 1990). Meta-analysis of the highest-quality family
studies produced an estimated odds ratio for increased risk for
MD in first-degree relatives of MD probands of 2.84 (Sullivan
et al., 2000). Surprisingly, no high-quality adoption study of MD
has been performed, so our evidence of the role of genetic
factors in its etiology comes solely from twin studies. While the
first of these also date to early in the 20th century, only six
high-quality studies were identified in the Review completed in
2000 (Sullivan et al., 2000). Meta-analysis estimated heritability
for MD to be 37% (95% confidence intervals 31–42). There
was no evidence from these studies that shared environmental
factors contributed meaningfully to the familial aggregation for
MD. One particularly large-sample twin study of MD estimated
the heritability of MD at 38% (Kendler et al., 2006).
Epidemiological studies of MD have consistently shown a
higher prevalence rate for women (Weissman et al., 1993,
1996). Therefore, twin researchers have been interested in
asking whether the heritability of MD differs across sexes and,
more interestingly, whether the same genetic factors impact on
risk for MD in men and women. The two major studies that
have addressed this question found reassuringly similar answers
(Kendler et al., 2001, 2006). In both studies, MD was appreciably
more heritable in women than in men (40% versus 30% and 42
versus 29%, respectively) and clear evidence was found for
sex-specific genetic effects with genetic correlations estimated
at +0.55 and +0.63. A substantial proportion of genetic risk
factors for MD appeared to be shared in men and women. How-
ever, these results also predict that when the individual genetic
variants that impact on risk for MD are definitively characterized,
an appreciable proportion of themwill be relatively sex specific in
their effect.
Genome-wide Association Studies
Table 1 summarizes the nine published genome-wide associa-
tion studies for MD. GWASs are typically carried out in two
stages: a discovery phase, in which the entire genome is
screened, and a replication phase, in which a subset of SNPs
are tested in an independent cohort. Some studies report the
replication and discovery results separately; others combine
Table 1. Summary of Genome-wide Association Studies of Major Depression
Sample
Origin Sample Cases Controls SNPs Phenotype Marker OR p Value Position
Lewis et al., 2010
UK Discovery 1,636 1,594 471,747 RMD rs9416742 0.719 1.30 3 107 chr10:60542444
UK Meta 1,418 1,918 – – rs606149 1.248 2.57 3 106 chr1:193921298
Muglia et al., 2010
Europe Meta (two
samples)
1,359 1,782 494,678 RMD rs4238010 0.58 5.80 3 106 chr12:4118067
Sullivan et al., 2009
Netherlands Discovery 1,738 1,802 435,291 MD rs2715148 0.79 7.70 3 107 chr7:82449785
Netherlands Replication 6,079 5,893 – – rs2715148 NA 8.20 3 101 chr7:82449785
Shyn et al., 2011
U.S. Discovery 1,221 1,636 382,598 RMD 901;
MD 735
rs12462886 0.76 1.73 3 106 chr19:29263440
U.S. Meta 3,957 3,428 – – rs1106634 1.295 6.78 3 107 chr8:20065799
Shi et al., 2011
U.S. Discovery 1,020 1,636 671,421 RMD 1,000;
MD 20
rs17077450 1.61 1.83 3 107 chr18:65285279
Wray et al., 2012
Australia/
Europe/U.S.
Discovery 2,431 3,673 1,251,157 RMD 1,145;
MD 1,286
rs182358 0.78 8.80 3 106 chr1:97462900
Australia/
Europe/U.S.
Meta 5,763 6,901 – – rs12446956 1.22 1.10 3 106 chr16:73501786
Ripke et al., 2013b
Australia/
Europe/U.S.
Discovery 9,240 9,519 1,235,109 RMD/MD rs11579964 0.846 1.00 3 107 chr1:224538690
Australia/
Europe/U.S.
Replication 6,783 50,695 – – rs1969253 1.049 4.79 3 106 chr3:183876262
Kohli et al., 2011
Europe/U.S. Discovery 353 366 365,676 MD/RMD rs1545843 2.84 5.53 3 108 chr12:84563818
Europe/U.S. Replication 3,738 10,635 – – rs1545843 1.315 1.40 3 109 chr12:84563818
Rietschel et al., 2010
German Discovery 604 1,364 491,238 MD rs2765493 1.45 2.26 3 107 chr1:157797750
German Meta 1,013 1,905 – – rs7713917 0.75 1.48 3 106 chr5:78828999
This table gives the number of cases and controls for each GWAS and summarizes results. The sample sizes listed are those used in the discovery
phase, replication, and meta-analyses (meta). The number of SNPs given is that used in the association analysis, which in some cases (Wray et al.,
2012; Ripke et al., 2013b) includes imputed data. The highest scoring markers are listed for each study, with their odds ratio (OR) and chromosomal
location. Studies used different inclusion criteria; these are summarized under the column headed phenotype, in which ‘‘RMD’’ is recurrent major
depression and ‘‘MD’’ is major depression. Where provided, the numbers of each phenotypic category are listed.
Neuron
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meta-analysis. Information on sample sizes for the two phases
is shown in Table 1.
A simple summary of Table 1 is that nothing significant has
been found and indeed many of the papers and reviews of this
field make that point (e.g., Cohen-Woods et al., 2013). However,
one paper claims a genome-wide significant association: a
marker within a gene desert on chromosome 12 (Kohli et al.,
2011). We need to consider not only whether this finding is likely
to be true, but also whether the negative findings are meaningful.
In short, how do we assess false-positive and false-negative
rates in Table 1?
Interpreting the results presented in Table 1 requires an under-
standing of what GWAS detects. GWAS interrogates commonvariation in the genome, usually variants with frequencies greater
than 5%, and typically requires a genome-wide significance
threshold of 53 108 (Pe’er et al., 2008) (this threshold depends
on a number of factors, including the number of variants tested,
also listed in Table 1). For the diallelic SNPs that are genotyped
on GWAS arrays, allele frequencies are usually reported as the
frequency of the least common allele (which will always be
<0.5). This is the minor allele frequency (MAF).
Genotypes from dense sets of SNPs are partially, and locally,
correlated (Sachidanandam et al., 2001). The pattern of correla-
tion is nonrandom, since recombination does not occur uni-
formly across the genome but is localized to hotspots (McVean
et al., 2004), giving rise to blocks of linkage disequilibrium. The
extent of linkage disequilibrium (that is to say the degree ofNeuron 81, February 5, 2014 ª2014 Elsevier Inc. 485
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Figure 1. Power to Detect a Locus using GWAS
Simulated data are plotted to assess power under two different sets of con-
ditions: varying the size of the locus effect (expressed as an odds ratio [OR])
and varying the number of loci used in the GWASs. Results are shown for an
Affymetrix 500K array (which yields approximately 400,000 useful genotypes
per individual) and simulations using all variants in HapMap (release 2). The
simulations are taken from Spencer et al. (2009). The significance level was set
at 5 3 108. Sample size is shown for the number of cases required; the
simulations assume an equal number of controls.
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Reviewcorrelation between markers) is one determinant of the ability of
a set of markers on a genotyping array to detect genetic signal.
An important consequence is that genotyping only a subset of
loci captures most of the common variation in the genome.
Conversely, if a causative variant is not correlated with any
markers on a genotyping array, it cannot be detected. The
degree to which genotyping arrays capture genomic information
is partly population specific, because population history affects
the extent of linkage disequilibrium. Thus, linkage disequilibrium
tends to increase the further away a population is from Africa
(Conrad et al., 2006), consistent with the hypothesis that humans
migrated out of Africa, experiencing severe population bottle-
necks on the way to colonizing the rest of the world (DeGiorgio
et al., 2009; Jakobsson et al., 2008). Standard GWAS
approaches do not work so well in African populations (Teo
et al., 2010).
One explanation for the failure of GWAS applied to MD might
be that the causative variants, or markers sufficiently close to
them, have not been genotyped on the available arrays. In fact,
due to the blocks of linkage disequilibrium, in non-African popu-
lations GWAS is remarkably effective at detecting a large fraction
of common variants of reasonable effect size (odds ratios greater
than 1.2) that contribute to complex traits, even though a very
small fraction of the total amount of sequence variation segre-
gating in a population is actually genotyped. To illustrate this,
Figure 1 shows the results of simulations that compare GWAS486 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.carried out using an Affymetrix 500K genotyping array, with the
results from using all the variants in HapMap (Frazer et al.,
2007). Even this relatively sparse array (current platforms interro-
gate millions of variants) has power of 82% (for a sample size of
9,000) to detect a locus with an odds ratio ofR1.2, compared to
88% with the complete set of SNPs (9,240 is the largest discov-
ery sample size used in GWAS of MD [Ripke et al., 2013b]). In
other words, differences in coverage between chips do not
translate into big differences in power. Furthermore, imputation
(Howie et al., 2009) using the very high density of variants
available from the 1000 Genomes Project (Abecasis et al.,
2010), has further extended the scope of genotyping arrays to
interrogate millions of ungenotyped variants. In short, failure of
GWAS to detect common variants (MAF > 5%) conferring risk
to MD is unlikely to be due to insufficient information about these
variants from genotyping arrays.
The most likely explanation for the failure of GWAS for MD is
that studies have been underpowered to detect the causative
loci (Wray et al., 2012). While GWAS coverage of common vari-
ants is good, GWAS requires large sample size in order to obtain
adequate power to detect variants of small effect (odds ratios
less than 1.2). In the following sections, we treat with common
variants and the power of GWAS (and candidate gene studies)
to find them. We turn later to the detection of rare variants of
larger effect.
Figure 1 demonstrates the nonlinear relationship between
sample size and effect size for common variants. To detect loci
with an odds ratio of 1.1 or less, sample sizes in the tens of thou-
sands will be required (note that this depends on the prevalence
of the disease; in the following discussions, we assume that MD
has a prevalence of 10%). Table 1 shows that the largest GWAS
forMDused 9,240 cases and 9,519 controls (Ripke et al., 2013b).
Figure 1 shows that such a sample has 90% power to detect
loci with an odds ratio ofR1.2; it will detect effects of this magni-
tude or greater at more than 93% of all known common variants.
Note that the one positive finding reported in Table 1 is an outlier:
no other GWAS detected the signal (Kohli et al., 2011). The study
used a discovery sample of 353 cases and 366 controls to
detect, at genome-wide significance, an association between
MD and a marker next to the SLC6A15 gene (Kohli et al.,
2011). Without further replication, the status of this finding is
dubious and is likely to be a false positive.
While Table 1 only includes GWASs of MD, there are also a
number of studies of phenotypes that are genetically related to
MD, such as the personality trait of neuroticism (Kendler et al.,
1993; Shifman et al., 2008) or depressive symptoms (Foley
et al., 2001; Hek et al., 2013). These studies are also negative.
The largest is a study of depressive symptoms in 34,549 individ-
uals that reports one, unreplicated, p value of 4.78 3 108.
Overall, we can conclude that no study has robustly identified
a locus that exceeds genome-wide significance for MD or genet-
ically related traits. We can also conclude that GWAS results
have set some constraints on the effect sizes likely to operate
at common variants contributing to susceptibility to MD.
Candidate Genes
Candidate gene studies of MD have generated many publica-
tions but few robust findings. At the time of writing (2013),
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returned more than 1,500 hits. Almost 200 genes have been
subject to testing, many by multiple groups (Bosker et al.,
2011; Lo´pez-Leo´n et al., 2008). The difficulty, common in this
area of research, is that few groups agree with each other.
Resolution of conflicting results is usually attempted through
meta-analysis and Table 2 summarizes data for 26 genes
analyzed by meta-analysis, of which seven yield a significant
(p < 0.05) result: 5HTTP/SLC6A4, APOE, DRD4, GNB3,
HTR1A, MTHFR, and SLC6A3.
We can use the results from Table 1 to interpret the results
presented in Table 2. First, we note that the mean effect size
(expressed as an odds ratio) across the studies that report a
significant effect is 1.35. Second, all of the variants tested,
whether significant or not, are common; none have an MAF
less than 10%, and the mean is 38% (column headed MAF in
Table 2). This means that the results of GWAS are relevant (recall
that GWAS interrogates common variants). Virtually all of the
candidate variants should be detectable by the published
GWAS, particularly if imputation is used to obtain data from
markers not present on the arrays (Howie et al., 2009) (Figure 1).
The fact that the candidate variants do not occur in Table 1 sug-
gests that the results in Table 2 are false positives (recall that the
largest published GWAS has greater than 80% power to detect
an odds ratio greater than 1.2).
Most GWASs include a section reporting the analysis of vari-
ants in candidate genes, and by providing a much larger sample
size than almost any of the meta-analyses listed in Table 2, their
findings are likely to be more robust than the meta-analyses.
Boomsma and colleagues tested 92 SNPs in 57 candidate genes
in a GWAS sample of 1,738 cases and 1,802 controls (Bosker
et al., 2011). Two SNPs (in C5orf20 [Willis-Owen et al., 2006]
and in NPY [Heilig et al., 2004]) scored p values less than 0.05,
where four would have been expected by chance. The finding
is therefore compatible with no effect at any locus tested. At
the gene level (testing for enrichment of significant SNPs), two
genes passed the 5% threshold, TNF (Jun et al., 2003) and the
norepinephrine transport (NET) (Inoue et al., 2004), again
compatible with chance expectations. Wray and colleagues
tested 180 candidate genes, and after correcting for the number
of tests carried out, found that no candidate gene was signifi-
cantly associated (Wray et al., 2012).
Table 2 shows the power of each meta-analysis, using the
effect size estimated from each meta-analysis (Purcell et al.,
2003) and assuming a disease prevalence of 10%. The mean
odds ratio estimated over all candidate gene meta-analyses is
1.15, requiring a sample size of greater than 3,000 cases. Only
six meta-analyses use sample sizes in excess of 3,000, and
just two of these six reported a significant finding. Note that for
those studies reporting a significant result, the mean power
was only 60%.
In summary, the data from Table 2 are consistent with a lack of
significant findings in any candidate gene meta-analysis. More-
over, the meta-analyses discussed here represent less than a
quarter of all the genes tested in the literature (and a smaller frac-
tion of the variants). With lower sample sizes than reported in the
meta-analyses, the findings for individual genes are weaker than
for those reported in Table 2.However, lack of evidence does not mean an effect can be
excluded; the negative findings are also compatible with a lack
of power to detect an effect. In fact, as we discuss below, esti-
mates of the likely number of genetic variants contributing to
MD risk run into the thousands. Given that about 18,000 genes
are expressed in the brain (Lein et al., 2007), it would not be
surprising if some of the candidates in Table 2 are true risk
variants, but nowhere near the effect size currently considered
plausible. This raises the question, so far unanswered, at what
point can we say a candidate has been excluded.
Nevertheless the conclusion is straightforward: candidate
gene studies provide little convincing support for the involve-
ment of any candidate gene in MD. This point should be born
in mind by all those wishing to use association data to support
a particular explanation of the biological causes of depression.
Neuroscientists sometimes claim that genetic results can be
interpreted as evidence in favor of their particular theory (Duman
et al., 1997; Holsboer, 2000; Luscher et al., 2011; Samuels and
Hen, 2011). Any such claims should be treated with extreme
caution.
The Contribution of Common Variants to Disease Risk
GWAS data can be used to constrain further the likely genetic
architecture of MD, by using marker results that do not reach
genome-wide significance. This is important because it might
be that the genetic architecture of MD consists primarily of
rare but relatively large effect loci. For example, it could be that
there are many susceptibility alleles with frequencies much
less than 5% and odds ratios greater than 3. Nothing we have
so far said has excluded this possibility. However, GWAS results
make that extremely unlikely, as can be appreciated from the
following argument.
Suppose that the genetic architecture of MD consists of
many small-effect loci, smaller than can be detected at
genome-wide significance by currently available samples. For
example, suppose the odds ratio for these risk variants are
1.05 and suppose the variants have a frequency of 50% (alleles
with a higher frequency are easier to detect, so this is a conser-
vative assumption). Power to detect a single variant of this
effect size at this frequency in a sample size of 10,000 cases
and 10,000 controls is less than 0.001%, at a p value of 1 3
107 and disease prevalence of 10% (Purcell et al., 2003).
But there is a 67% chance that such a variant will have a
p value less than 0.5. This means that if all SNPs are ranked
by their p values, then p values less than 0.5 will be enriched
with SNPs that contribute to disease susceptibility. In other
words, if there are small-effect variants contributing to MD,
then the distribution of SNP p values will depart from null ex-
pectations. This method is referred to as polygenic scoring
and has been used to investigate the polygenic nature of com-
plex traits.
A second class of method uses the SNP data to estimate
genetic similarity and thereby assess heritability. GWAS SNPs
are common variants, shared by descent from common ances-
tors. Regions of the genome contributing to disease susceptibil-
ity will be enriched among those with the same disease. The
degree of sharing of common variants will reflect the heritability
of the trait, at least that portion due to such common variation.Neuron 81, February 5, 2014 ª2014 Elsevier Inc. 487
Table 2. Candidate Gene Meta-analyses
Reference
Number of
Studies
Number of
Cases
Number of
Controls p Value OR 95% CI Variant MAF Power
Number for
80% Power
5-HTR2A
Anguelova et al., 2003 7 768 959 0.597 0.96 0.84–1.11 rs6311 0.44 6.2% 55,781
Jin et al., 2013 11 1,491 2,937 0.12 NA NA rs6311 0.44 NA NA
5HT-6R
Fukuo et al., 2010 4 701 2,422 0.406 0.94 0.80–1.08 rs1805054 0.17 8.4% 19,021
5HTTLPR/SLC6A4
Clarke et al., 2010 39 6,836 14,903 0.007 1.09 1.02–1.16 44 bp ins/del 0.43 65.8% 9,575
Anguelova et al., 2003 11 941 2,110 0.198 1.08 0.96–1.22 44 bp ins/del 0.43 12.3% 11,958
Anguelova et al., 2003 10 592 2,094 >0.5 NA NA intron 2 VNTR 0.35 NA NA
Furlong et al., 1998 4 275 739 0.049 1.2 1.00–1.45 44 bp ins/del 0.43 17.3% 2,112
Lasky-Su et al., 2005 14 1,961 3,402 0.28 1.05 0.96–1.14 44 bp ins/del 0.43 10.5% 32,911
Lo´pez-Leo´n et al., 2008 22 3,752 5,707 <0.05 1.11 1.04–1.19 44 bp ins/del 0.43 51.6% 7,356
Lo´pez-Leo´n et al., 2008 8 NA NA NS 1.33 0.78–2.27 intron 2 VNTR 0.35 NA NA
ACE
Wu et al., 2012 15 2,479 7,744 NS 1.15 1.02–1.3 Ins/del intron 16 0.45 65.9% 3,465
Lo´pez-Leo´n et al., 2006 4 586 5,169 >0.1 0.85 0.55–1.3 Ins/del intron16 0.45 33% 1,992
Lo´pez-Leo´n et al., 2008 8 NA NA NS 1.08 0.97–1.2 Ins/del intron16 0.45 NA NA
BDNF
Gyekis et al., 2013 3 331 688 0.103 0.83 0.67–1.04 rs16917204 0.24 20.7% 2,001
Gyekis et al., 2013 2 285 746 0.527 1.16 0.74–1.82 rs2030324 0.46 22.5% 2,340
Gyekis et al., 2013 2 777 1,541 0.831 0.98 0.85–1.14 rs988748 0.26 5.4% 193,287
Gyekis et al., 2013 23 4,173 12,747 0.402 0.96 0.89–1.05 rs694 0.43 14.1% 43,058
Chen et al., 2008b 9 3,879 3,151 0.918 1 0.94–1.07 rs694 0.43 NA NA
Lo´pez-Leo´n et al., 2008 8 NA NA NS 1.01 0.93-1.09 rs694 0.43 NA NA
Verhagen et al., 2010 14 2,812 10,843 >0.1 1.06 0.94–1.19 rs694 0.43 19.5% 18,385
CLOCK
Kishi et al., 2011 6 930 2,305 0.47 0.95 0.83–1.09 rs1801260 0.22 8.4% 25,381
COMT
Lo´pez-Leo´n et al., 2008 6 NA NA NS 0.98 0.86–1.13 rs4680 0.39 NA NA
DRD3
Lo´pez-Leo´n et al., 2008 4 541 606 NS 1.06 0.85–1.34 rs6280 0.45 13.8% 5,721
DRD4
Lo´pez Leo´n et al., 2005 5 318 814 0.003 1.73 1.29–2.32 48 bp ins/del 0.45 95.6% 185
GABRA3
Lo´pez-Leo´n et al., 2008 6 NA NA NS 0.91 0.68–1.2 CA repeat intron 8 0.29 NA NA
GNB3
Lo´pez-Leo´n et al., 2008 3 375 492 <0.05 1.38 1.13–1.69 rs5443 0.48 51.2% 743
HTR1A
Kishi et al., 2009 7 1,658 2,046 0.0327 0.821 0.695–0.984 rs6295 0.48 65.9% 2,315
Lo´pez-Leo´n et al., 2008 4 NA NA NS 1.16 0.98–1.38 rs6295 0.48 NA NA
Kishi et al., 2013 13 3,199 4,380 0.006 0.87 0.78–0.96 rs6295 0.48 61.9% 4,901
HTR1B
Lo´pez-Leo´n et al., 2008 3 NA NA NS 0.96 0.77–1.2 rs6296 0.35 NA NA
HTR2A
Anguelova et al., 2003 7 768 959 0.597 0.96 0.84–1.11 rs6311 0.44 6.2% 55,781
Jin et al., 2013 11 1,491 2,937 0.12 NA NA rs6311 0.44 NA NA
Gu et al., 2013 4 780 1,528 0.1 0.91 0.74–1.12 rs6311 0.44 13.9% 8,229
(Continued on next page)
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Table 2. Continued
Reference
Number of
Studies
Number of
Cases
Number of
Controls p Value OR 95% CI Variant MAF Power
Number for
80% Power
Lo´pez-Leo´n et al., 2008 4 NA NA NS 1.01 0.85–1.21 rs6311 0.44 NA NA
Lo´pez-Leo´n et al., 2008 8 NA NA NS 0.96 0.84–1.09 rs6313 0.43 NA NA
HTR2C
Lo´pez-Leo´n et al., 2008 2 NA NA NS 1.03 0.85–1.25 rs6318 0.17 NA NA
HTR6
Fukuo et al., 2010 4 701 2,422 0.406 0.94 0.80–1.08 rs1805054 0.17 8.4% 19,021
MAOA
Lo´pez-Leo´n et al., 2008 4 NA NA NS 0.86 0.65–1.13 VNTR promoter 0.34 NA NA
MTHFR
Peerbooms et al., 2011 17 3,341 13,840 0.579 1.016 0.96–1.07 rs1801133 0.32 6.2% 250,625
Lewis et al., 2006 9 1,241 1,1021 0.003 1.36 1.11–1.67 rs1801133 0.32 99.1% 518
Gilbody et al., 2007 10 1,280 10,429 <0.05 1.14 11.04–1.26 rs1801133 0.32 43.4% 3,121
Zintzaras, 2006 5 291 897 >0.1 1.15 0.97–1.36 rs1801133 0.32 13.4% 3,223
Lo´pez-Leo´n et al., 2008 6 875 3,859 <0.05 1.2 1.07–1.34 rs1801133 0.32 51.5% 1,719
Gaysina et al., 2008 4 1,222 835 0.39 0.96 0.84–1.09 rs1801133 0.32 6.4% 80,906
NET/SLC6A2
Zhao et al., 2013 6 1,673 1,410 0.78 1.02 0.911.13 rs5569 0.27 5.5% 281,312
Zhao et al., 2013 6 1,681 2,938 0.78 1.03 0.841.27 rs2242446 0.26 6.7% 90,329
Lo´pez-Leo´n et al., 2008 3 NA NA NS 0.97 0.8–1.18 rs2242446 0.26 NA NA
DAT/SLC6A3
Lo´pez-Leo´n et al., 2008 3 151 272 <0.05 2.06 1.25–3.4 VNTR 3-UTR 0.48 90.1% 112
Lo´pez-Leo´n et al., 2008 3 NA NA NS 0.94 0.84–1.05 VNTR 3-UTR 0.48 NA NA
TPH1
Chen et al., 2008a 10 1,812 2,223 >0.1 NA NA rs1800532 0.36 NA NA
TPH1
Lo´pez-Leo´n et al., 2008 9 NA NA NS 0.88 0.71–1.09 rs1800532 0.36 NA NA
This table summarizes the data frommeta-analyses of candidate genes in which variants have been tested for association with major depression (MD).
The table is sorted by gene to allow comparison between studies of the same gene. Note that some studies test different variants within the same gene.
The column headed ‘‘Variant’’ gives the variant tested. Throughout the table, ‘‘NA’’ means ‘‘not available’’ and NS ‘‘nonsignificant.’’ The table gives
sample sizes for the number of studies included in the meta-analysis (Number of Studies), the total number of cases and controls (Number of Cases
and Number of Controls), the p value (where available), the odds ratio (OR), and associated 95% confidence interval (95% CI). Where the variant is an
SNP, an rs number is provided along with the minor allele frequency (MAF) in European populations. For repeats, the frequency of the commonest
variant is given. The power of each study, expressed as a percentage (Power) was calculated from the odds ratio of the meta-analysis, using the
Genetic Power Calculator (Purcell et al., 2003). Power was calculated assuming an additive model and with marker allele frequencies set to 0.5
(a conservative assumption).
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individuals with the disease, it is possible to estimate the herita-
bility from SNPs (hence sometimes called SNP heritability).
There are currently two implementations of this idea (So et al.,
2011; Yang et al., 2011).
Two papers report SNP heritabilities for MD ranging from 21%
(Lee et al., 2013) to 30% (Lubke et al., 2012). The discrepancy
between SNP- and family-based heritability estimates (of about
38%) is in part attributable to the fact that causal variants are not
in linkage disequilibrium with genotyped markers (Yang et al.,
2010a); this means that the SNP-based heritability is a lower
bound on that arising from common variants.
Even though the SNP heritabilities have wide confidence
intervals (from 15%–50%), they provide a critically important
constraint on our understanding of the genetics of MD: theyindicate that common variants of small effect (with odds ratio
less than 1.2, and probably much less) make a large contribution
to the genetic susceptibility to the disease, accounting for more
than 50% of the heritability. Indeed, the SNP heritability is
consistent with the view that the genetic basis of MD consists
of many thousands of independently acting loci, each of very
small effect, that contribute to disease susceptibility. Before
we consider some alternative possibilities, we pursue what this
conclusion means for genetic studies of MD. What is needed
to find robust, genome-wide significant association? Can we
estimate the sample size needed?
Complex traits show clear differences in the number of
samples required to obtain a significant finding. Figure 2 shows
results for two diseases (cancer and Crohn’s disease) and two
quantitative traits (height and weight) (Park et al., 2010). WhichNeuron 81, February 5, 2014 ª2014 Elsevier Inc. 489
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Figure 2. GWAS Sample Size
Sample sizes (horizontal axis) required for a GWAS to have 80% probability of
detecting the number of loci shown on the vertical axis, at a significance level
of 5 3 108. Results are shown for four complex traits: two disease and two
quantitative phenotypes. The graph assumes that the number of loci detected
increases linearly with increasing sample size (data are from Frayling et al.,
2007; Lango Allen et al., 2010; Loos et al., 2008; Park et al., 2010; Scuteri et al.,
2007; Speliotes et al., 2010; Thorleifsson et al., 2009; Wen et al., 2012; Willer
et al., 2009).
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Figure 3. The Effect of Disease Prevalence on Sample Size to Detect
at Least One Locus for Major Depression
Sample sizes (horizontal axis) required for a GWAS to have 80% probability of
detecting at least one locus contributing to the risk of major depression,
plotted against disease prevalence (vertical axis). In most surveys, major
depression has a prevalence of about 10%. The genetic architecture of major
depression is assumed to be either similar to height (black continuous line) or
weight (red dotted line).
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Reviewgenetic architecture is most similar to that of MD? If we could
answer this question, we would be in a good position to estimate
the sample sizes needed to detect genetic loci, thus informing
our interpretation of existing data, and the design of future exper-
iments.
Wray and Visscher asked this question about the genetic
architecture of schizophrenia (Wray and Visscher, 2010). Their
answer involved finding a phenotype with a genetic architecture
predicted to be similar to schizophrenia and for which many
genetic loci have been found. They suggested, from similar
heritability estimates, risks to relatives, and the disease preva-
lence, that the genetic architecture of schizophrenia resembles
that of height. In order to compare genetic analysis of height
with schizophrenia, they assume that genetic liability to schizo-
phrenia is quantitative and that the dichotomous nature of
schizophrenia arises because the number of predisposing alleles
in some individuals exceeds a certain threshold. For example, an
individual with predisposing alleles at 100 loci or more might
present with schizophrenia, while someone with fewer such
alleles would show no symptoms. By considering that disease
prevalence represents the fraction of individuals whose genetic
susceptibility exceeds this threshold, and that schizophrenia
has otherwise the same genetic architecture as height, it is
possible to apply what we know from height GWAS data to esti-
mate sample sizes needed to detect schizophrenia risk loci
(Yang et al., 2010b).
In order to compare the power to detect a locus affecting a
disease in a case-control study with the power to detect a locus490 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.affecting a quantitative trait (assuming that both have the same
genetic architecture and heritability), Visscher and colleagues
show that only the disease prevalence and proportion of cases
and controls need be known (Yang et al., 2010b). This means
that we can estimate sample sizes for a GWAS of MD by
comparing it with a quantitative trait that has a similar genetic
architecture and for which loci have been found. But which quan-
titative trait is appropriate?
Weight (ormore properly bodymass index) might be an appro-
priate model: many loci have been mapped (Berndt et al., 2013;
Speliotes et al., 2010) and it has a heritability similar to MD
(a recent estimate based on 20,000 sibling pairs gave 40%
[Hemani et al., 2013], though this is lower than a large meta-anal-
ysis of twin data [Nan et al., 2012]). In Figure 3, we show results
under the assumption that MD has a similar genetic architecture
to weight (red dotted line) or to height (black continuous line)
(Yang et al., 2010b). We estimated the number of samples
needed for an MD GWAS to have 80% power to detect at least
one locus, for different disease prevalences.
If MD has a genetic architecture similar to weight (red dotted
line), then, for a disease prevalence of 10% (typical of most
surveys of MD), a sample size of more than 50,000 cases will
be needed to detect at least one genome-wide significant hit.
About 10,000 cases are needed if MD has a genetic architecture
similar to height. Figure 3 also shows that disease prevalence
has a big impact on power. For example, while power to detect
a variant that explains 0.08%of the variance on liability toMDwill
be 4%, in a sample size of 10,000 cases and 10,000 controls,
Neuron
Reviewpower in schizophrenia (prevalence 1%) is approximately 50%
for the same sample size.
The effect of disease prevalence (shown on the vertical axis) is
not linearly related to sample size. In order to find genes with a
smaller sample size, we need to collect a sample that has a lower
prevalence. That could be achieved in one of two ways. If MD is
truly a quantitative phenotype, then the extremes of the distribu-
tion will represent a less prevalent form of disease. We could
take disease that is so severe that it has a prevalence of 0.5%
or lower, so that fewer than 20,000 cases would provide 80%
power to detect at least one locus. The problem is finding the
appropriate severity scale.
Alternatively, we could identify rare subtypes of depression
that are less prevalent and we hope represent a more homoge-
nous condition than MD broadly defined. Ideally, such subtypes
would have a different genetic architecture, veering more toward
that of height than of weight, so that much smaller samples are
needed. Do such heritable subtypes of MD exist? We address
this question below. We start however with a review of the ge-
netics literature todeterminewhether theremight be rarebut rela-
tively large-effect loci that GWASs have been unable to detect.
The Contribution of Rare Variants to Disease Risk
The data we have summarized so far are compatible with the
hypothesis that the genetic basis of MD arises from the joint ef-
fect of very many loci of small effect, with odds ratios of much
less than 1.2. However, it is also compatible with the existence
of larger effect loci, under two alternative (but not incompatible)
hypotheses; first, some of the heritability of MD is explained by
rare relatively large-effect loci; second, larger effect sizes would
be observed if more homogeneous heritable phenotypic group-
ings could be identified.We consider in this section whether rare,
large-effect variants might exist and return to the issues of
phenotypic homogeneity later.
It is sometimes forgotten that linkage studies provide informa-
tion about rare, relatively penetrant susceptibility loci. Family-
based designs are typically not well powered to detect the small
effects found in GWASs. For example, on average, siblings share
50%of their genome.Where two siblings have the same disease,
departure from this 50%sharing indicates regions that harbor risk
variants; but since the SD for sharing is large (approximately
3.7%), large sample sizes are required to detect a significant
departure. Family designs can however detect one form of
genetic variation that is hidden fromGWASs: the joint effect of in-
dependent, rare, mutations in the same gene (recall that GWASs
are effective for common variants). In a linkage study, the effects
of independent mutations will combine together, since the unit of
analysis in linkage (theaveragedistancebetween recombinations
in the human genome in a single meiosis) is a much larger
genomic region than is thecase for associationanalyses. In cases
in which linkage asserts that there is an effect but association
fails to detect one, then one explanation is allelic heterogeneity:
multiple effects exist in the gene but on different haplotypes.
Linkage studies are summarized in Table 3. Results are
reported as a logarithm of the odds (LOD) score, rather than a
p value. The majority of the studies reported in Table 3 used an
affected sibling design (in which two siblings have MD). In this
design, an LOD score of 2.2 is suggestive evidence for linkage(expected to occur once by chance in a genome scan), an
LOD score greater than 3.6 represents significant linkage
(expected to occur by chance with a probability of 5%), and an
LOD score of 5.4 is highly significant (probability of chance
occurrence is less than 0.1%) (Lander and Kruglyak, 1995).
Table 3 makes four points. First, there is clear heterogeneity
between studies. The outlier here is the Zubenko study (Zubenko
et al., 2003), which reports more loci at higher levels of signifi-
cance than all the others. Second, there is evidence for poor
internal consistency. Three groups report data in multiple publi-
cations, usually because they acquired additional data (Utah
families [Abkevich et al., 2003; Camp et al., 2005], DeNt [Breen
et al., 2011; McGuffin et al., 2005], and GenRED [Holmans
et al., 2004, 2007; Levinson et al., 2007]). The additional samples
collected by the GenRED consortium failed to confirm the 15q
linkage reported in their initial paper (Holmans et al., 2004). The
authors considered that the first finding might be a false positive,
that the second finding might be a false negative, or that both
findings were true, the difference being attributable to variation
in the clinical features of the families (Holmans et al., 2007).
Third, there are overlaps in the locations identified by linkage
results (Table 3). The confidence intervals for the position of
loci found by linkage studies are notoriously broad (Roberts
et al., 1999), so that overlaps between localizations often occur
by chance. However, if we restrict analysis to a window of just
5 Mb, then five regions are repeatedly found: chromosome 11,
75–80 Mb (Breen et al., 2011; Zubenko et al., 2003), chromo-
some 15, 37–42 Mb (Zubenko et al., 2003; Camp et al., 2005),
chromosome 15, 87–92 Mb (Breen et al., 2011; Holmans et al.,
2004, 2007; Levinson et al., 2007), chromosome 3, 4–9 Mb
(Breen et al., 2011; Middeldorp et al., 2008), and chromosome
2, 64–68 Mb (Middeldorp et al., 2008; Schol-Gelok et al.,
2010). This is partly, but not entirely, due to the large number
of loci found in one study (Zubenko et al., 2003), a study that
has attracted criticism (e.g., unusually low simulation-based
LOD score thresholds reported for analyses without covariates
[Levinson, 2006]), so we cannot come to any firm conclusions,
but this result suggests that some of the signal may be true.
Finally, there is some evidence that sex differences matter.
Four groups report differences in linkage results when the anal-
ysis incorporates sex as a covariate. As predicted by the twin re-
sults summarized earlier, some loci appear to be sex specific
(Abkevich et al., 2003; Camp et al., 2005; Holmans et al., 2007;
McGuffin et al., 2005; Zubenko et al., 2003).
One interpretation of the linkage studies is that rare but rela-
tively penetrant variants might contribute to the genetic risk.
Nevertheless, it is also possible that the linkage findings could
be explained as false positives or the overinterpretation of
nonsignificant results. In this respect, it is useful to consider
the results of a study of weight in 20,240 siblings (from 9,570
nuclear families) showing that a highly polygenic genetic archi-
tecture (such as that underlyingMD) can falsely indicate the pres-
ence of large-effect loci in a linkage analysis (Hemani et al., 2013).
There is some limited evidence from other sources that
Mendelian-acting mutations give rise to MD. Attempts to fit
morbid riskdata to singlemajor locusmodels haveall been incon-
clusive (Gershon et al., 1976; Goldin et al., 1983; Price et al.,
1985), as have been attempts to find markers that cosegregateNeuron 81, February 5, 2014 ª2014 Elsevier Inc. 491
Table 3. Linkage Studies
Phenotype Study Name Families Individuals %F
Clinical
Instrument
Peak
Marker
Peak
LOD
Score Marker Location Sex
Zubenko et al., 2003
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D1S1597 3.6 chr1:13,684,
108-13,884,418
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D1S1609 2.7 chr1:243,965,
857-244,166,112
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D2S427 2.77 chr2:232,106,
263-232,306,614
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D5S1503 3.32 chr5:98,071,
660-98,272,056
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D5S1505 3.74 chr5:119,001,
596-119,201,988
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D8S1477 1.74 chr8:31,966,
957-32,167,504
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D10S1221 3.01 chr10:57,429,
886-57,630,151
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D10S2470 2.61 chr10:92,264,
596-92,464,872
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D11S1984 4.2 chr11:1,466,
686-1,667,029
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D11S2002 2.1 chr11:79,865,
382-80,065,662
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D15S1012 1.96 chr15:38,907,
527-39,107,917
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D18S858 2.93 chr18:
54796986-
54997312
–
RMD 375 pairs; MD 520 pairs;
mood disorder 610 pairs;
depression spectrum 520
Pittsburgh
families
81 1,242 51.63 SADS-L D19S586 2.49 chr19:9,704,
793-9,905,143
–
Abkevich et al., 2003
RMD 784; MD 161; BPD 162 Utah families 110 1,357 68.98 BPS D12S1600 6 chr12:99,200,
748-99,401,155
Male
Camp et al., 2005
RMD 1,513; anxiety 1,141,
of which only 718 used
Utah families 87 NA NA – D3S1752 3.81 chr3:97,645,
283-97,845,588
–
RMD 1,513; anxiety 1,141,
of which only 718 used
Utah families 87 NA NA – D7S517 2.89 chr7:4,397,
915-4,598,292
–
RMD 1,513; anxiety 1,141,
of which only 718 used
Utah families 87 NA NA – D18S1270 3.75 chr18:61,292,
502-61,492,816
–
RMD 1,513; anxiety 1,141,
of which only 718 used
Utah families 87 NA NA – D15S515 2.88 chr15:43,497,
354-43,697,543
Male
(Continued on next page)
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Table 3. Continued
Phenotype Study Name Families Individuals %F
Clinical
Instrument
Peak
Marker
Peak
LOD
Score Marker Location Sex
RMD 1,513; anxiety 1,141,
of which only 718 used
Utah families 87 NA NA – D4S2631 2.6 chr4:155,863,
840-156,064,129
Male
McGuffin et al., 2005
RMD 929 DeNt 417 929 70.94 SCAN D1S450 3.03 chr1:9,485,
419-9,685,791
Female
RMD 929 DeNt 417 929 70.94 SCAN D12S1613 1.57 chr12:107,538,
542-107,738,864
–
RMD 929 DeNt 417 929 70.94 SCAN D13S170 1.47 chr13:81,009,
094-81,209,378
–
RMD 929 DeNt 417 929 70.94 SCAN D1S2667 2.54 chr1:11,386,
961-11,587,307
Female
RMD 929 DeNt 417 929 70.94 SCAN D1S508 2.19 chr1:7,507,
384-7,707,656
Female
RMD 929 DeNt 417 929 70.94 SCAN D12S1683 1.29 chr12:106,085,
479-106,285,844
–
RMD 929 DeNt 417 929 70.94 SCAN D15S1047 1.14 chr15:81,041,
079-81,241,425
–
RMD 929 DeNt 417 929 70.94 SCAN D15S999 1.08 chr15:86,145,
362-86,345,589
–
Breen et al., 2011
RMD 2,164 DeNt NA 2,412 72.43 SCAN D3S1515 4.01 chr3:6,311,
334-6,511,566
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D7S513 1.91 chr7:11,551,
237-11,751,614
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D11S937 1.75 chr11:77,754,
318-77,954,608
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D10S1653 1.6 chr10:15,577,
832-15,778,169
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D1S450 0.75 chr1:9,485,
419-9,685,791
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D12S1613 <1 chr12:107,538,
542-107,738,864
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D15S999 1.41 chr15:86,145,
362-86,345,589
–
RMD 2,164 DeNt NA 2,412 72.43 SCAN D13S170 <1 chr13:81,009,
094-81,209,378
–
Holmans et al., 2004
RMD 809 GenRED 297 1,039 79.00 DIGS D15S652 3.73 chr15:92,417,
335-92,617,665
–
Holmans et al., 2007
RMD 1,720; MD 28 GenRED 656 2,176 79.63 DIGS D15S652 3.05 chr15:92,417,
335-92,617,665
–
RMD 1,720; MD 28 GenRED 656 2,176 79.63 DIGS D17S974 4.77 chr17:10,418,
666-10,618,972
Male
RMD 1,720; MD 28 GenRED 656 2,176 79.63 DIGS D8S1106 3.49 chr8:12,735,
859-12,936,149
Male
Levinson et al., 2007
RMD 1,687 GenRED 631 2,161 79.00 DIGS NA 4.69 chr15:92,600,000 –
Pergadia et al., 2011
MD and smoking 220 Australian/
Finland
116 810 56.79 CIDI D3S1304 4.14 chr3:6,819,
242-7,019,583
–
(Continued on next page)
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Phenotype Study Name Families Individuals %F
Clinical
Instrument
Peak
Marker
Peak
LOD
Score Marker Location Sex
Middeldorp et al., 2009
MD Australian/
Dutch
133 558 61.12 CIDI ATA58E08 2.1 chr17:19,426,
481-19,426,503
–
MD Australian/
Dutch
133 558 61.12 CIDI D8S504 1.9 chr8:917,
443-1,117,767
–
MD Australian/
Dutch
133 558 61.12 CIDI GATA66D01 1.7 chr2:66,951,
054-67,151,286
–
Schol-Gelok et al., 2010
Symptoms of MD 115 Dutch ERF 45 1,144 71.3 HADS-D
and CES-D
rs715271 0.93 chr2:57133160 –
Symptoms of MD 115 Dutch ERF 45 1,144 71.3 HADS-D
and CES-D
rs890478 0.99 chr2:64540177 –
Symptoms of MD 115 Dutch ERF 45 1,144 71.3 HADS-D
and CES-D
rs372169 2.14 chr5:3180951 –
Symptoms of MD 115 Dutch ERF 45 1,144 71.3 HADS-D
and CES-D
rs1965277 2.27 chr11:134850365 –
Symptoms of MD 115 Dutch ERF 45 1,144 71.3 HADS-D
and CES-D
rs1688128 2.66 chr19:3029918 –
The table summarizes information from linkage studies of major depression. Most studies are represented by more than one publication (reporting
additional data, or more in-depth analyses), so the second column provides a study name to indicate which studies report on the same data sets.
Studies used different inclusion criteria; these are summarized under the column headed phenotype where RMD is recurrent major depression,
MD is major depression, BPD is bipolar disease. Where provided, the numbers of each phenotypic category are listed. The table gives the acronym
of the clinical instrument used, the peak marker, and associated LOD score for nonparametric linkage (some studies also report parametric results
[Schol-Gelok et al., 2010]), without added covariates. In cases where a significant sex difference was found, this is reported in the column headed Sex.
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1978; Weitkamp et al., 1980; Wilson et al., 1989). A review of
the online catalog of Mendelian disorders (OMIM) identified four
single gene disorders in which MD is present as a clinical feature
(Table 4). In addition (and not reported in the table), there arewell-
known relationships betweenMDand familial Cushing syndrome
andParkinson disease. The examples in Table 4 are rare, such as
Perry syndrome, for which eight families are known worldwide,
and typically present with additional phenotypes that would not
lead them to be classified among the majority of cases of MD.
Table 4 contains one example of a Mendelian mutation that
underlies pure MD: Wolfram syndrome, a rare autosomal reces-
sive disorder due to a mutation on the short arm of chromosome
4 (Polymeropoulos et al., 1994). The important point here is that
Wolfram is a recessive condition. The disease itself (in homo-
zygotes) is characterized by a broad spectrum of psychiatric
and neurological disorders, but heterozygote carriers show a
purer MD phenotype: in one report, out of 11 individuals carrying
aWolframmutation, eight were hospitalized for major MD, signif-
icantly more than the three relatives expected if there were no
association between psychiatric hospitalizations and mutations
at this locus (Swift and Swift, 2005). The authors argue that ‘‘if
the population frequency of wolframinmutations that predispose
carriers to psychiatric illness is about 1%, with an odds ratio of
7.1, wolframin mutation carriers would be estimated to be about
7% of patients hospitalized for MD’’ (Swift and Swift, 2005).
Overall, we cannot rule out the possibility that rare large-effect
risk alleles exist, but we also cannot extend much hope for their494 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.discovery. It is possible that risk alleles with odds ratios between
3 and 4, occurring at low frequencies (less than 5%), make a
contribution to MD, but their discovery will require either a new
generation of genotyping arrays, interrogating rare variants, or
the deployment of population-scale sequencing.
Genetics and the Nosology of MD
The second hypothesis to explore is the idea that larger-effect
loci might be detected if MD were to be analyzed differently.
For example, consider the possibility that MD is not one but
two disorders that cannot be differentiated on a clinical basis
alone. Suppose that 50 variants contribute to disease through
one pathway (leading to one subtype of MD) and 50 to a second
pathway (leading to the second subtype). Unbeknownst to in-
vestigators, a study contained equal numbers of the two sub-
types. Since variation in the first pathway is irrelevant to disease
susceptibility in the second subtype, the genetic effect of loci
acting on one pathway is reduced by half, and power is similarly
reduced. This point is not merely important in helping design
genetic studies, it is critically important for their interpretation.
Without knowledge of the existence of two unrelated mecha-
nisms, it would be difficult, perhaps impossible, to interpret the
results of the study. We would be left guessing whether the
100 variants represented one, two, or more mechanistic path-
ways.
Do subforms of genetically homogeneous MD exist? A large
literature addresses this issue, not all of it readily summarized;
here we tackle two questions that are key to understanding
Table 4. Mendelian Conditions in which Major Depression Has Been Listed as a Phenotype
MIM Name Clinical Features Prevalence Inheritance Gene
#168605 Perry sydrome The earliest and most prominent
symptom may be MD not responsive
to antidepressant drugs or
electroconvulsive therapy. Sleep
disturbances, exhaustion, and
marked weight loss are features.
Eight families in the world Dominant DCTN1
#314250 Dystonia 3, torsion,
X-linked; DYT3
The odds ratio for overall MD was
increased OR = 2.85, 95% CI =
0.56–5.14) in patients with DYT3
compared to the control group.
5.24 in 100,000 on Panay Island,
Philippines
X-linked TAF1
#128100 Dystonia 1, torsion,
autosomal dominant; DYT1
Carriers of DYT1 are over four times
more likely than noncarriers to exhibit
recurrent MD. Relative risk of 3.62
In France, an estimated disease
frequency of 0.13 in 100,000
Dominant DYT1
#222300 Wolfram syndrome 1; WFS1 Additional clinical features include
diverse psychiatric disorders
Heterozygous carriers of the Wolfram
syndrome, estimated to represent
approximately 1% of the United States
population, are predisposed to MD.
Recessive WFS1
The column headed MIM provides the reference number in Mendelian Inheritance in Man (http://www.omim.org).
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from other disorders? Second, is MD one disorder or two, or
more?
How Separate Is MD from Other Disorders?
Two disorders that most frequently overlap diagnostically with
depressive illness are anxiety and bipolar disorder. The prevail-
ing view is that MD is highly comorbid with anxiety: about 60%
of individuals with MD report a lifetime history of one or more
anxiety disorders (Alonso et al., 2004a; Angst, 1993; Blazer
et al., 1994; Hunt et al., 2004; Kessler et al., 1996, 2003; Merikan-
gas et al., 1996; Mineka et al., 1998; Pini et al., 1997; Zimmerman
et al., 2008). The most closely related condition, symptomati-
cally, is generalized anxiety disorder (GAD). Longitudinal studies
indicate that while GAD precedes the occurrence of MD in about
one-third of cases, conversely in about a third of cases, MD
precedes GAD (Moffitt et al., 2007).
While there is general agreement in the literature for comorbid-
ity between anxiety andMD, bipolar disorder andMD are usually
thought to be separable. A distinction between unipolar (MD
only) and bipolar (episodes of MD and mania) can be drawn on
the basis that bipolar disorder’s onset age is on average 15 years
younger than unipolar, recursmore frequently, is associated with
different personality types (MD is associated with neuroticism
and bipolar with sensation seeking or extraversion) (Perris,
1966b), and has an increased risk of bipolar illness in relatives
(Gershon et al., 1982; Lieb et al., 2002; Weissman et al., 1984).
Genetics provides a way of testing the diagnostic uniqueness
or otherwise of MD by determining the degree of genetic corre-
lation between diseases. Do the same genetic loci that increase
susceptibility to MD also increase susceptibility to other disor-
ders? Two quantitative Reviews (meta-analyses) agree that there
is a high genetic correlation between anxiety and MD (Cerda´
et al., 2010; Middeldorp et al., 2005). Of 16 twin studies that
report genetic covariation between anxiety and MD, all found
that the genetic correlation between GAD and MD is not sig-nificantly different from unity. Demirkan and colleagues have
recently confirmed the genetic correlation between MD and
anxiety using SNP data to generate genetic risk scores (Demir-
kan et al., 2011). Thus, for anxiety, the comorbidity can be attrib-
uted, in part, to a common genetic basis. At a genetic level, GAD
and MD are the same.
For many years, genetic data have been employed to support
a separation of unipolar from bipolar affective illnesses: rela-
tives of those with bipolar are more likely to develop bipolar,
and conversely relatives of unipolar probands more likely to
develop unipolar illness (MD, in other words) (Perris, 1966a).
With few exceptions, subsequent studies have confirmed this
observation: bipolar illness aggregates in the families of bipolar
probands much more than in families of unipolar probands
(Weissman et al., 1984). However, it is also true that in compar-
ison to the general population, relatives of both bipolar and uni-
polar probands have increased risks of both forms of affective
disorder (Gershon et al., 1982; Lieb et al., 2002; Weissman
et al., 1984). The risk for bipolar disorder in relatives of MD
probands is only modestly increased, approximately 2-fold
across studies (on a relative risk scale) (Tsuang and Faraone,
1990). Conversely, there is about a 3-fold increase in risk of
developing unipolar depression for a first-degree relative with
bipolar disorder. Note that the base rates of unipolar and bipo-
lar illnesses are very different: about 1% for bipolar as against
10% for unipolar. Altogether, a third to over a half of the affec-
tively ill family members of bipolar patients manifest depressive
illness (Weissman et al., 1984). Gershon argued from a study of
1,254 relatives of probands and controls that different affective
disorders represent ‘‘thresholds on a continuum of underlying
multifactorial vulnerability’’ (Gershon et al., 1982). If true, then
bipolar disorder would be a more severe form of unipolar
depression.
Genetic correlation data to test this hypothesis are limited: one
twin study of 67 pairs of twins with bipolar and 177 with unipolar
depression yielded a genetic correlation of 0.65 between theNeuron 81, February 5, 2014 ª2014 Elsevier Inc. 495
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Reviewtwo disorders. However, the data were not consistent with the
threshold model, namely that bipolar is a more severe subform
of unipolar (McGuffin et al., 2003). A larger study of 486 twin pairs
with affective illness provided some support for the threshold
model, but the number of bipolar probands was small, so power
to discriminate models was low (Kendler et al., 1995b).
Using SNP heritability approaches (So et al., 2011; Yang et al.,
2011), there are now estimates of the genetic correlations
between MD and bipolar disorder (Lee et al., 2013). The genetic
correlation with bipolar disorder was 0.47 (SE 0.06), compatible
with the twin-study genetic correlation of 0.64 (McGuffin et al.,
2003). This finding suggests an overlap between unipolar and
bipolar illnesses in which some loci contribute to both condi-
tions. Consistent with this, genetic analysis of loci that act across
disorders has been used to implicate calcium-channel signaling
in the etiology of affective disorders (Cross-Disorder Group of
the Psychiatric Genomics Consortium, 2013).
However, before concluding that molecular genetic analysis
trumps the phenotypic separation of unipolar from bipolar, two
points should be born in mind. GWAS results show that the
majority of heritability can be assigned to many loci of small
effects. How many that might be depends on the unknown
contribution of rarer variants of large effect, but we can provide
a rough estimate by assuming that depression is a quantitative
trait, in which MD is one extreme (following the same reasoning
for the power estimates for a successful MD GWAS [Yang et al.,
2010b]). From the distribution of effect sizes of other quantitative
traits, we can estimate the number of loci required to explain the
heritability of MD. Assuming an exponential distribution (Gold-
stein, 2009), about 2,500 loci are required to explain half the
heritability. This estimate is conservative, since the distribution
of variants more closely follows a Weibull distribution than an
exponential (Park et al., 2010). In short, the number of variants
required to explain MD heritability implies that about one in five
genes expressed in the brain are likely to be involved.
If thousands of variants confer susceptibility to MD, then this
could explain a genetic correlation with other psychiatric disor-
ders. We have no reason to expect the genetic architecture of
anxiety, BP, or schizophrenia to be very different from MD:
they are all likely to involve many loci of small effect, and they
are all, at some level, brain disorders. Indeed, Ripke and col-
leagues estimate that 8,300 independent SNPs contribute to
the genetic basis of schizophrenia, accounting for 50% of the
variance in liability to schizophrenia (Ripke et al., 2013a). With
18,000 genes expressed in the brain (Lein et al., 2007), and
each disorder influenced by variants in thousands of genes, ge-
netic correlation may be inevitable.
The second point to note about the correlation between MD
and other disorders concerns how well the phenotypic distinc-
tions have been drawn. For example, no one has been able to
identify features that distinguish with high accuracy episodes
of MD in unipolar cases from episodes of MD in cases with bipo-
lar illness. Furthermore, there is evidence that MD and BP share
more characteristics than is sometimes appreciated: several
authors have claimed that a large number of patients diagnosed
with unipolar disorder have features of bipolar illness (Angst
et al., 2010, 2011; Cassano et al., 2004; Zimmermann et al.,
2009). When symptoms of subthreshold mania are sought496 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.(elevated mood, irritable mood, or increased activity), a large
proportion of unipolar cases are found to qualify: up to half of
all cases with unipolar illness (Angst et al., 2010, 2011; Zimmer-
mann et al., 2009). However, subthreshold diagnoses depend
critically on the quality of the assessments and the exact inter-
pretation of what constitutes subclinical mania (it is easy to
confuse a state of hypomania with elation from ‘‘normal’’ causes
like falling in love, or getting a grant funded in grim times, or hy-
peractivity from the agitation that occurs in some depressive
subtypes).
We can conclude that genetic and phenotypic classifications
concur in identifying considerable overlap between anxiety and
MD,withmixed support for a distinction betweenMDand bipolar
disorder. The genetic data point to genetic overlap, but this
may be, to some extent, a consequence of the polygenicity of
complex traits. We turn next to the question of whether there
exists a pure MD, rarer and harder to distinguish from bipolar
than currently acknowledged, which has at least partly distinct
genetic roots. Or more generally, we ask, are there genetically
homogenous subtypes of MD?
Is Major Depression One Disorder?
Those unfamiliar with the literature debating the division of MD
into subtypes may be surprised not only at the diversity of the
proposed classificatory systems employed (e.g., dimensional,
hierarchical, or categorical) but also at the vehemence with
which each position has been defended, or more usually
attacked (Eysenck, 1970; Parker, 2000). The importance of this
acrimonious debate is the extent to which genetic research
strategies might resolve it and potentially guide interpretation
of the underlying pathogenic mechanisms. Genetic data do in
fact indicate heterogeneity. Most striking is the effect of sex.
As reviewed above, genetic effects on MD differ between
men and women. It is more heritable in women and the genetic
correlation between the sexes is approximately +0.60. To put
this in perspective, the figure is comparable to the genetic corre-
lations estimated between bipolar disorder and MD from twin
studies (0.64; McGuffin et al., 2003) and SNP heritability (0.47;
Lee et al., 2013). How canMDbe one condition, when the degree
of genetic correlation between the sexes is of the same magni-
tude as that between two supposedly separate disorders?
Heterogeneity is also evident at a phenotypic level. Currently,
MD is diagnosed when depressed mood, or a loss of interest or
pleasure in daily activities, is present for more than 2 weeks, and
five or more out of nine symptoms (including low mood and loss
of interest) occur nearly every day. Do these nineDSM symptom-
atic criteria for MD reflect a single underlying genetic factor?
Surprisingly, only one study has addressed this question
(Kendler et al., 2013). The best-fitting model to explain MD
concordance in 7,500 adult twin pairs required three genetic
factors, reflecting the psychomotor/cognitive, mood, and neuro-
vegetative features of MD. As might have been predicted from a
set of criteria chosen on the basis of clinical judgment rather than
psychometric properties or validation from biological features,
the nine DSM symptomatic criteria for MD do not appear to
represent a single underlying genetic factor.
Second, do certain forms of MD breed true? That is to say, if
we look in families, do we find that related individuals share
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an atypical pattern of increased sleep and appetite (rather than
the opposite); does this represent a heritable feature that might
identify a genetically homogenous subtype? While some studies
examining the inheritance of clinical features find that they do
not breed true (Weissman et al., 1986, 2006), latent class
analysis of 14 symptoms of depression, assessed in 1,029
female twin pairs, revealed that members of a twin pair concor-
dant for depression were significantly more likely than expected
to share features of the latent class-derived syndrome (Kendler
et al., 1996). This raises a third question, as to which, if any, fea-
tures characterize an inherited form of MD.
Is there amore genetic formofMD?An old distinction between
‘‘endogenous’’ and ‘‘reactive’’ MD (Gillespie, 1929) is based
upon the presumed occurrence of depressive episodes that
were independent of precipitating events, compared to episodes
that were an exaggerated reaction to life events. Is it possible
that the endogenous form of MD is more genetically determined
than others? The short answer to that question is no; in fact,
contrary to the hypothesis that subjects whose MD appears to
be devoid of precipitating events should have increased genetic
predisposition (indexed by greater family history), the opposite is
true: those reporting more stressful life events are more likely to
have a family history (Kendler and Karkowski-Shuman, 1997).
However, this finding does indicate, as the large literature on
familial MD confirms (reviewed in Rutter et al., 1999; Sullivan
et al., 2000), that clinical differences exist between those with
and those without a family history of MD. Distinguishing features
are relatively nonspecific: those with a family history of MD have
more clinically severe illness, tend to present at an earlier age,
and suffer higher rates of recurrence (Kendler et al., 1994,
1999; Lieb et al., 2002; Weissman et al., 2006).
Environmental influences are also likely to stratify MD. Evi-
dence from twin studies (Kendler et al., 1995a, 2004; Silberg
et al., 2001) indicate that genetic risk factors for MD not only alter
average risk but also impact on sensitivity to the depressogenic
effects of environmental adversities, particularly various forms of
childhood maltreatment and recent stressful life events. The
finding of increased genetic susceptibility to environmental
stressors, or in short a gene by environment interaction, sug-
gests the possibility of subdividing MD on the basis of en-
vironmental effects: theoretically genetic effects will be more
homogeneous, relatively larger, and easier to detect in popula-
tions with clearly defined exposures.
While twin studies have shown that aggregate genetic risk
factors for MD interact with stressful events, in recent years
the field has been preoccupied with one of the many possible
ways in which this effect might be explained at the molecular
level. The dispute is whether or not the serotonin transporter
5-HTTLPR variant is involved in a gene by environment inter-
action. The original studywas carried out on a longitudinal cohort
in New Zealand, and empirical literature dealing with whether
that finding is robust, and replicable, is unclear and considerably
polarized (Caspi et al., 2010; Kaufman et al., 2010; McGuffin
et al., 2011).
Two meta-analyses found no evidence for an interaction
(Munafo` et al., 2009; Risch et al., 2009), while one meta-analysis
concluded that there was an effect (Karg et al., 2011). The differ-ence lies in the way studies were selected for themeta-analyses.
The authors of the positive GxE meta-analysis take the view that
the effect of GxE is broad: ‘‘rather than focus on a specific class
of studies, we sought to perform a meta-analysis on the entire
body of work assessing the relationship between 5-HTTLPR,
stress, and MD’’ (Karg et al., 2011). The one study that came
closest to replicating the original design, a longitudinal study of
a birth cohort in New Zealand, failed to replicate the first report
(Fergusson et al., 2011). All that we can reasonably conclude is
that current attempts to subdivide MD on the basis of inter-
actions with environmental effects using candidate genes are
unlikely to yield quick insights into the origins of the disease.
Conclusion
Genetic analysis of MDwas recently recognized to be among the
greatest challenges facing health researchers (Collins et al.,
2011). For some complex traits, including schizophrenia (Ripke
et al., 2013a), there are now a number of verified genetic loci
that contribute to disease susceptibility; in some cases, their
discovery has implicated disease mechanisms, casting light on
known, suspected, or indeed novel biological processes that
explain why some people fall ill (Teslovich et al., 2010; van der
Harst et al., 2012). Research findings in MD have yet to reach
this stage. Despite convincing evidence for a genetic con-
tribution to disease susceptibility, there has been a dearth of
substantive molecular genetic findings. Nevertheless, there is
an impressive quantity of relevant literature. Does it amount
to anything? Yes, because negative findings impart important
lessons.
The failure of GWAS analysis of more than 9,000 cases of
MD (Ripke et al., 2013b) to find robust evidence for loci that
exceed genome-wide significance is compatible with a para-
digm in which the majority of the genetic variance is due to the
joint effect of multiple loci of small effect. Twin studies and
SNP-based heritability tests of the samples used for genome-
wide association discount the possibility that there are no ge-
netic effects to be found, leaving two nonmutually exclusive
possibilities: either the effects are smaller than expected and/
or the disorder is heterogeneous: different diseases might
manifest with similar symptoms (incorrectly identified as the
same illness), or there may be many different pathways to the
same outcome (different environmental precipitants trigger MD
in different ways, according to the genetic susceptibility of the in-
dividual).
We have reviewed evidence that indicates that MD is hetero-
geneous. This is clearly seen in the difference between sexes:
genetics sees a greater difference between MD in men and
MD in women than physicians recognize between anxiety and
MD. However, while there is considerable agreement in the liter-
ature that MD has heterogeneous causes, there is much less
agreement about its homogeneity as a clinical disease (Parker,
2000). Attempts to subdivide MD on the basis of inheritance
have so far yielded only limited fruit: relatively nonspecific fea-
tures, recurrence, and earlier onset indicate greater genetic
predisposition.
The picture is consistent with a fairly undifferentiated
phenotype emerging as the final common outcome of diverse
processes, a process called equifinality in the developmentNeuron 81, February 5, 2014 ª2014 Elsevier Inc. 497
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Reviewliterature. The list of possible pathways is large: in addition to
long-running favorites such as abnormalities of monoamine
metabolism (including postreceptor components of the down-
stream cAMP signaling pathway [Duman et al., 1997]) and
impaired corticosteroid receptor signaling (Holsboer, 2000),
more recent hypotheses include the involvement of neurotro-
phins (Samuels and Hen, 2011), fibroblast growth factors (both
ligands and receptors) (Turner et al., 2012), GABAergic deficits
(Luscher et al., 2011), and epigenetic changes, specifically alter-
ations in methylation and acetylation profiles at the promoters of
glucocorticoid receptors and brain-derived neurotrophic factor
(McGowan et al., 2009). Genetics does not support the primacy
of one theory over another; indeed as our Review of the candi-
date gene literature indicates, genetics does not support any
of the biological theories put forward to date.
Recommendations
Our Review indicates two pathways forward. First, there is no
reason to suppose that undifferentiated MD is intractable to
GWAS, but success will require very large sample sizes
(Figure 3). However, interpreting the results of such a study is
likely to be challenging. We have seen that MD is highly co-
morbid with anxiety, and etiologically heterogeneous, at both
genetic and environmental levels.Without information on comor-
bidity, known risk factors, and clinical phenotypes, the role of
each locus will be unclear. Some will be sex specific, some will
act only in situations of environmental stress, and others will
predispose to anxiety. Genetic studies will need to include an
extensive amount of phenotypic information if we are to make
sense of hard-won mapping results.
Second, our Review indicates that we should not abandon
attempts to concentrate on subtypes ofMD. So far, studies using
recurrent and early-onset MD have been no more successful
than those that examine undifferentiated MD, but this may be
due to lack of power. If we consider MD as part of a quantitative
trait (representing liability to depression), then using a sample of
more extreme cases would be equivalent to analyzing a rare
disease (as Figure 3 demonstrates). Even a small improvement
in genetic tractability could result in a large saving in the number
of samples that need to be analyzed (reducing from 50,000 to
20,000, for example).
The problem is that we do not know for sure how to determine
the scale on which severity is measured: is it the number of
episodes of MD, the length of episodes, the number of symp-
toms, or some other feature or combination of features? Further-
more, the severity scale needs to differentiate cases with higher
genetic risk, not those cases resulting largely from environmental
adversities. Alternatively, subdividing MD on the basis of one or
more clinical features (e.g., typical versus atypical vegetative
features, standard versus postpartum onset), sensitivity to envi-
ronmental stress, or sex, might identify a rarer, or at least a more
genetically homogenous, subtype. At present, deciding which
features to investigate is likely to be an ad hoc enterprise.
Without knowing beforehand which to use, studies will need to
be comprehensive, collecting as broad a range as possible of
clinical features and known or putative risk factors.
Forty years ago, a perceptive Review of depressive disorders
in Science (Akiskal and McKinney, 1973) argued that a psycho-498 Neuron 81, February 5, 2014 ª2014 Elsevier Inc.analytic model of MD as object loss (a proximal cause of MD)
could be conceptualized as loss of reinforcement, or loss of
control over reinforcement, then subject to experimental in-
vestigation in animal models, and integrated with anatomical,
biochemical, and pharmacological data as a process occurring
in the diencephalic centers of reward. In this view, MD is a final
common pathway, a decrease in the functional capacity of the
reward system. Since then, MD has begun to appear as a rela-
tively thin covering serving to unite a plethora of independently
acting mechanisms. Genetic analyses can identify risk variants,
both rare and common, and in so doing cast much needed illu-
mination on the biology of the commonest psychiatric disorder.
The difficulties of sample size and clinical differentiation are
daunting but unavoidable if we are to take advantage of the
promise that genetics makes.
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